Alvotech Files Annual Report with the SEC

Alvotech (NASDAQ: ALVO) filed its Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission on March 30, 2026.

Rhea-AI Summary

Alvotech (NASDAQ: ALVO) filed its Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission on March 30, 2026. The filing incorporates parts of the Alvotech Annual Report 2025 and is publicly available on the SEC website and Alvotech investor relations site.

For investor or media inquiries, Alvotech provided contact emails for media and investor relations on its investor site.

Argus Mar 31 session

+4.26% close to close Open Argus

Details

News Market Reaction – ALVO

On Mar 31, the first trading day after this news, ALVO closed 4.26% above the previous close.

Data tracked by StockTitan Argus for the Mar 31 session.

Historical Context

5 past events · Latest: Mar 18

5 events

1. Mar 18

   Earnings results

   24h Move

   -5.8%

   Q4 and FY 2025 revenue and EBITDA growth with reaffirmed 2026 guidance.

2. Mar 04

   Earnings scheduling

   24h Move

   +2.4%

   Announcement of dates for Q4 and full-year 2025 results and conference call.

3. Feb 26

   Insider share transfer

   24h Move

   -4.1%

   Disclosure of intra‑group transfer of 2,701,617 shares at USD 4.74.

4. Feb 11

   Share capital change

   24h Move

   -6.7%

   Issuance of 12,500,000 shares to subsidiary, increasing total issued share count.

5. Feb 05

   Clinical results

   24h Move

   -2.0%

   Positive pivotal PK study results for AVT80 biosimilar to Entyvio.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

form 20-f, u.s. securities and exchange commission

2 terms

form 20-f regulatory

"has filed its Annual Report 2025 on Form 20-F for the financial year 2025"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

u.s. securities and exchange commission regulatory

"with the U.S. Securities and Exchange Commission (SEC), incorporating by reference"

The U.S. Securities and Exchange Commission is a government agency responsible for overseeing the stock market and protecting investors. It sets rules to ensure that companies share truthful information and that trading is fair, helping to maintain trust in the financial system. This oversight is important because it helps prevent fraud and ensures that investors can make informed decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REYKJAVIK, Iceland, March 30, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Alvotech Annual Report 2025. The report is available on the SEC’s website, www.sec.gov, as well as in the investor relations section of Alvotech’s website at https://investors.alvotech.com/financials.

For further information, contact:

Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com

Investors
Dr. Balaji V Prasad (US)
Patrik Ling (SE)
Benedikt Stefansson (IS)
alvotech.ir@alvotech.com

About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in biosimilars by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira^® (adalimumab), Stelara^® (ustekinumab), Simponi^® (golimumab), Eylea^® (aflibercept) and Prolia^®/Xgeva^® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alvotech (ALVO) file with the SEC on March 30, 2026?

Alvotech filed its Annual Report 2025 on Form 20-F with the SEC on March 30, 2026. According to Alvotech, the filing incorporates parts of the Alvotech Annual Report 2025 and is available on the SEC and company investor websites for review.

Where can investors access Alvotech (ALVO) Annual Report 2025 Form 20-F?

The Annual Report 2025 Form 20-F is available on the SEC website and Alvotech's investor relations site. According to Alvotech, the report can be accessed at www.sec.gov and https://investors.alvotech.com/financials for download and review.

Does the Alvotech (ALVO) SEC filing include the Annual Report 2025?

Yes, the Form 20-F filing incorporates parts of the Alvotech Annual Report 2025 by reference. According to Alvotech, investors should consult the incorporated Annual Report sections via the SEC filing or the company's investor relations pages.

Who should investors contact for questions about Alvotech (ALVO) Annual Report 2025?

Investors can contact Alvotech investor relations via the provided email addresses listed on the investor relations site. According to Alvotech, specific contacts include Dr. Balaji V Prasad, Patrik Ling, and Benedikt Stefansson at the posted investor relations email.

When did Alvotech (ALVO) announce the filing of its Annual Report 2025 on Form 20-F?

Alvotech announced the Form 20-F filing on March 30, 2026. According to Alvotech, the filing covers the financial year 2025 and is available immediately on both the SEC and Alvotech investor relations websites for public access.